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Co-trimoxazole (CTX) causes various forms of severe cutaneous adverse reactions 71 
(SCARs). This case-control study was conducted to investigate the involvement between genetic 72 
variants of human leukocyte antigen (HLA) and CYP2C9 in CTX-induced SCARs, including 73 
Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug reaction with 74 
eosinophilia and systemic symptoms (DRESS) in Thai patients. Thirty cases of CTX-induced 75 
SCARs were enrolled and compared with 91 CTX-tolerant controls and 150 general Thai 76 
population. Cases comprised 18 SJS/TEN and 12 DRESS patients. This study demonstrated that 77 
genetic association of CTX-induced SCARs was phenotype-specific. HLA-B*15:02 and HLA-78 
C*08:01 alleles were significantly associated with CTX-induced SJS/TEN, whereas the HLA-79 
B*13:01 allele was significantly associated with CTX-induced DRESS. In addition, a significant 80 
higher frequency of HLA-A*11:01-B*15:02 and HLA-B*13:01-C*03:04 haplotypes were 81 
detected in the group of CTX-induced SJS/TEN and DRESS cases, respectively. Genetic 82 
association of co-trimoxazole-induced severe cutaneous adverse reactions is phenotype-specific. 83 
Interestingly, these association was observed only in HIV infected patients but not in non-HIV-84 
infected patients.  85 









Co-trimoxazole (CTX), a combination of sulfamethoxazole and trimethoprim, 95 
sequentially blocks bacterial folate synthesis.
1 
CTX is useful in the treatment of a variety of 96 
bacterial, fungal, and protozoal infections.
2, 3
 The World Health Organization (WHO) have 97 
recommended the use of CTX prophylaxis in infants, children, and adolescents with HIV to 98 
prevent opportunistic infections.
4
 However, CTX is associated with severe cutaneous adverse 99 
reactions (SCARs), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), 100 
drug reaction with eosinophilia and systemic symptoms (DRESS), and fixed drug eruption 101 
(FDE).
5-8
 Sulfamethoxazole is metabolized to sulfamethoxazole hydroxylamine, which is further 102 
oxidized to nitrosulfamethoxazole. Nitrosulfamethoxazole binds covalently to host proteins, 103 
eliciting an IgE and/or a T cell mediated response to modified proteins manifesting in different 104 
forms of drug hypersensitivity.
9
  105 
Human leukocyte antigen (HLA) is the human major histocompatibility complex 106 
responsible for presentation of processed peptide antigens to T cells to initiate the adaptive 107 
immune response.
10
 There are three regions of the human MHC: class I region consists of HLA-108 
A, HLA-B, and HLA-C genes, class II region consists of HLA-DR, HLA-DQ, and HLA-DP genes, 109 
and class III region, which does not encode HLA molecules, consists of genes for complement 110 
components (C2, C4, factor B), 21-hydroxylase, tumor necrosis factors (TNFs), and others.
11
 111 
Several HLA alleles have been reported to be associated with CTX-induced SCARs. A recent 112 
case-control study in the Thai population reported an association between CTX-induced 113 
SJS/TEN and HLA-B*15:02 (odds ratio [OR] = 3.91 [95% confidence interval [CI]: 1.42-10.92], 114 
P=0.0037), HLA-C*06:02 (OR = 11.84 [95% CI: 1.24-566.04], P=0.0131) and HLA-C*08:01 115 
(OR = 3.53 [95% CI: 1.21-10.40], P=0.0108).
12
 In European patients the presence of HLA-B*38 116 
was significantly associated with sulfamethoxazole-related SJS/TEN, but the different allelic 117 
variants of HLA-B*38 did not show significant association with sulfamethoxazole-related 118 
SJS/TEN.
13
 Additionally, a strong association between SJS/TEN and trimethoprim alone was 119 
observed. (OR = 9.44, 95%CI = 3.83-23.25)
14
. This finding suggests that not only most common 120 
culprit sulfamethoxazole but also trimethoprim induce SJS/TEN in patients. A retrospective 121 
genome-wide association study (GWAS) in European subjects did not find any single-nucleotide 122 
polymorphisms (SNPs) with genome-wide significance when CTX-induced SJS/TEN cases were 123 
compared with controls.
15
 Highly polymorphic gene, CYP2C9 is a key factor in enzyme activity 124 
variation in various drug once this variant occurred. Recently, Clinical Pharmacogenetics 125 
Implementation Consortium (CPIC) recommends guidelines for CYP2C9 and HLA-B Genotype 126 
and Phenytoin Dosing
16
. There was the report of CYP2C9*3 association to phenytoin-induced 127 
SCARs in Thai epileptic children with odd ratio = 14.52 (95% CI = 1.18–∞, P-value = 0.044).
17
 128 
However, no study on the association between CYP2C9 and co-trimoxazole was performed.  129 
Until now, although one study has reported the association of HLA alleles and CTX-130 
induced SJS/TEN in the Thai population, there are no data on the association with other SCAR 131 
phenotypes such as DRESS.  In the present study, our aim was to identify and compare the HLA 132 
alleles associated with CTX-induced SJS/TEN and DRESS in Thai patients. 133 
Materials and Methods 134 
Patient recruitment 135 
 For our study, we included a total of 30 patients with CTX-induced SCARs (18 males 136 
and 12 females).  These patients were admitted to the hospital for treatment of CTX-induced 137 
SCARs between 2014 and 2017 and were prospectively enrolled in our study. The patients 138 
recruited in the present study are different from those previously reported by Kongpan et al.
13
 139 
The RegiSCAR criteria were used to diagnose and classify SCARs, 
18, 19
 and a 140 
dermatologist and allergist confirmed the diagnoses based on the photographs, pathological 141 
slides, clinical morphology, and medical records. SJS was defined as a mucocutaneous disorder 142 
characterized by skin rash and skin detachment affecting <10% of the body surface area. TEN 143 
was defined as skin detachment >30%. SJS-TEN overlap was defined as skin detachment of 10% 144 
to 30%. DRESS was characterized by acute skin rash, fever above 38°C, enlarged lymph nodes, 145 
internal organ involvement, and hematological abnormalities, including lymphocytosis or 146 
lymphocytopenia, eosinophilia, and thrombocytopenia. We evaluated co-trimoxazole was the 147 
causative drug of SJS/TEN or DRESS using Naranjo algorithm,
20
 the score of the algorithm of 148 
drug causality for epidermal necrolysis (ALDEN)
21
 and DRESS score. The cases defined as 149 
possible, probable and definite were recruited in this study. In some cases, in vitro assay (such as 150 
ELISpot) was performed. Two groups of control were used in the present study: 91 CTX-tolerant 151 
patients (which are the same group as previously reported by Kongpan et al.
13
) and 150 healthy 152 
Thai subjects which obtained from five regional groups of unrelated healthy Thai individuals. 153 
The individuals lived in the abovementioned regions for more than three generations
22
. 154 
This study was approved by the Ramathibodi Hospital Ethical Review Board, and the 155 
Khon Kaen Ethics Committee for Human Research, Khon Kaen University, Thailand.  Written 156 
informed consent was obtained from all the participants. 157 
HLA-A, -B and -C alleles genotyping 158 
 For all the study subjects, DNA extraction using MagNAPure Compact Nucleic Acid 159 
Isolation kits was performed based on magnetic-bead technology (Roche Applied Science, 160 
Mannheim, Germany). DNA was aliquoted and stored at -20ᴼC before HLA typing.  Genotyping 161 
of HLA-A, -B and -C alleles were determined by the polymerase chain reaction with sequence-162 
specific oligonucleotide probes (PCR-SSOP) hybridization method using Luminex
®
IS 100 163 
system (Luminex Corporation, Austin, Texas, USA) with well-established protocols. 164 
CYP2C9 genotyping 165 
The CYP2C9 variant alleles are routinely tested include CYP2C9*2 and*3 , CYP2C9*2 166 
(430C>T, rs1799853) and CYP2C9*3 (1075A>C, rs1057910) were genotyped by pre-designed 167 
TaqMan
®
 SNP genotyping assays using sequence primers and TaqMan MGB probes of 168 
CYP2C9*2 (assay ID: C_25625805_10) and CYP2C9*3 (assay ID: C_27104892_10) (Applied 169 
Biosystems, Foster City, CA).  170 
Statistical analysis 171 
 Statistical analyses were performed using SPSS statistical software package, version 18 172 
(SPSS Inc, Chicago, IL). To detect differences in the demographic of study population, an 173 
independent t-test was used for continuous variables. The ORs with corresponding 95% CIs were 174 
calculated to determine the association between the presence of the HLA loci and CTX-induced 175 
SCARs. Fisher's exact test was used to compare allele frequencies between cases and controls. 176 
Bonferroni correction was applied to adjust for multiple comparisons. P-values < 0.05 (two-177 
sided) indicated a statistical significance.  178 
In this study, we pooled data from a previous study by Kongpan et al.
13
 and the present 179 
study and compared the frequencies of HLA alleles in CTX-SJS/TEN cases and tolerant controls.     180 
Haplotype association analysis was carried out using the “haplo.stats” package.  181 
 182 
Results 183 
The demographic data of all the case are shown in Table 1. Our cohort comprised 13 184 
(43.33%) cases of CTX-induced SJS, 4 (13.33%) cases of CTX-induced TEN, 1 (3.33%) case of 185 
CTX-induced SJS/TEN overlap, and 12 (40.00%) cases of CTX-induced DRESS (a total of 30).  186 
The mean age of co-trimoxazole hypersensitive patients was 40.90±13.94 and 60.00% were 187 
male.  Most cases received CTX for prophylactic use among HIV-infected persons. There were 188 
no significant differences in gender, age, indication of drug administration, onset of reaction and 189 
co-morbidity.  190 
Mucosal involvement including eye, oral and genital mucosa, abnormal liver and renal 191 
function test were observed in SCARs patients (Table S1). Nine cases received monotherapy 192 
with CTX while the other 21 cases received concomitant medications. For 9 individuals, the 193 
CTX dose administered were not available in their medical records. Among 30 CTX-related 194 
SCARs, we found no CYP2C9*2 and *3 alleles which possibly interpreted as CYP2C9*1/*1 195 
(extensive metabolizer; EM) base on the frequency of this genotype in study population. The 196 
genotypes of HLA-A, HLA-B, HLA-C and CYP2C9 in the 30 cases with CTX-induced SCARs are 197 
shown in Table 2.  198 
Association of all CTX-induced SCARs with HLA alleles 199 
We compared the carrier frequencies of the HLA class I alleles in the 30 CTX-induced 200 
SCARs cases with the 91 CTX-tolerant controls and 150 healthy Thai population controls. The 201 
results are summarized in Table 3. 202 
  HLA-B*13:01 was observed in 43.33% (13/30) of cases, 16.48% (15/91) of tolerant 203 
controls, and 15.33% (23/150) of healthy controls. HLA-B*15:02 was observed in 30.00% (9/30) 204 
of cases, 10.99% (10/91) of tolerant controls, and 18.00% (27/150) of healthy controls. HLA-205 
B*13:01 and HLA-B*15:02 were significantly overrepresented in patients with CTX-induced 206 
SCARs as compared to CTX-tolerant controls with ORs of 3.88 (95% CI = 1.56-9.63, P=0.0025) 207 
and 3.47 (95% CI = 1.25-9.63, P=0.0201), respectively. Of the other HLA alleles, HLA-A*11:01 208 
allele showed the most significant association with CTX-induced SCARs cases with an OR of 209 
3.25 (95% CI = 1.34-7.89, P=0.0073). The frequency of HLA-A*02:07 allele was significantly 210 
decreased among the CTX-induced SCARs cases and was thus designated protective allele. 211 
HLA-C*07:27 and HLA-C*08:01 were also significantly associated with CTX-induced SCARs 212 
compared to CTX-tolerant controls with ORs of 31.08 (95% CI = 1.62-595.88, P=0.0032) and 213 
3.91 (95% CI = 1.38-11.06, P=0.0149), respectively. 214 
Haplotype analysis revealed that only the frequencies of the HLA-A*11:01-B*15:02 and 215 
HLA-B*13:01-C*03:04 haplotypes in the CTX-induced SCAR group were significantly different 216 
from those in the control groups. The OR for CTX-induced SCARs among patients with the 217 
HLA-A*11:01-B*15:02 haplotype was 4.36 (95% CI = 1.43–13.34, P= 0.0108), whereas the OR 218 
among those with the HLA-B*13:01-C*03:04 haplotype was 3.77 (95% CI = 1.27–11.19, 219 
P=0.0251). However, the significant associations of the HLA alleles and haplotypes disappeared 220 
after corrections for multiple testing (P <0.0025). 221 
Association of CTX-induced DRESS and HLA alleles  222 
We compared the carrier frequencies of HLA class I alleles in the 12 CTX-induced 223 
DRESS patients, in 91 CTX-tolerant controls, and in 150 healthy Thai population controls. The 224 
results are summarized in Table 4 (only the alleles and haplotypes of HLA that showed a 225 
significant association when compared with the CTX-tolerant controls and/or healthy population 226 
controls) are shown. 227 
As shown in Table 4, four alleles were significant in the CTX-induced DRESS group: 228 
HLA-A*11:01, HLA-B*13:01, HLA-C*03:04, and HLA-C*07:27.  Only the HLA-B*13:01 allele 229 
reached statistical significance after Bonferroni correction (75.00% versus 16.48%, P = 7.2x10
-5
, 230 
OR = 15.20, 95% CI = 3.68–62.83). 231 
Haplotype analysis revealed that the carrier rate of HLA-B*13:01-C*03:04 haplotype was 232 
significantly higher among patients with CTX-induced DRESS as compared to the CTX-tolerant 233 
controls (OR = 14.53, 95% CI = 3.74-56.47, P = 1.8x10
-4
). 234 
Association of CTX-induced SJS/TEN and HLA alleles 235 
We compared the carrier frequencies of HLA class I alleles in the 18 CTX-induced 236 
SJS/TEN patients, 91 CTX-tolerant controls, and 150 healthy Thai population controls. The 237 
results are summarized in Table 5 (only the alleles and haplotypes of HLA are shown that 238 
showed a significant association when compared with the CTX-tolerant controls and/or healthy 239 
population controls).  240 
None of HLA-A alleles were significantly associated with CTX-induced SJS/TEN. 241 
Interestingly, we identified an increased frequency of HLA-A*02:07 and HLA-A*33:03 alleles in 242 
the controls as compared to the CTX-induced SJS/TEN cases.  243 
A strong association between HLA-B*15:02 and CTX-induced SJS/TEN was confirmed 244 
with an OR of 5.16 (95% CI = 1.63–16.33, P = 0.0075). The HLA-B*38:02 allele which was 245 
observed in 33.33% (6/18) of CTX-induced SJS/TEN cases showed statistically significant 246 
difference. (OR = 4.05, 95% CI = 1.25-13.18, P = 0.0249).  247 
 We found that HLA-C*08:01 allele was detected more frequently in cases, with 7 of 18 248 
CTX-induced SJS/TEN possessing HLA-C*08:01 allele versus 9 of 91 of the CTX-tolerant 249 
controls (OR = 5.79, 95% CI = 1.79-18.70, P = 0.0049). In addition, we also found a significant 250 
association between HLA-C*07:27 allele and CTX-induced SJS/TEN with OR of 27.73 (95% CI 251 
= 1.27-604.11, P = 0.0259).  252 
The HLA-A*11:01-B*15:02 haplotype was found with a higher frequency in CTX-253 
induced SJS/TEN patient group than in CTX-tolerant control group (33.33% versus 7.69%, P = 254 
0.0074, OR = 6.00, 95% CI = 1.72–20.88). 255 
Association of CTX-induced SCARs and HLA alleles among the different subgroup. 256 
In subgroup analysis of HIV patients, 23 patients in case and 61 patients in tolerant group 257 
were analyzed. The significant association between HLA class I and CTX-induced SCARs was 258 
shown in Table 6. For DRESS group, 9 patients in case and 61 patients in tolerant group were 259 
analyzed. The HLA-A*11:01, HLA-B*13:01 and HLA-C*07:27 were statistically associated with 260 
CTX-induced DRESS with OR of 5.78, 95% CI = 1.11-30.25, P = 0.0376, OR of 11.55, 95% CI 261 
= 2.44-54.78, P = 0.0021 and OR of 41.00, 95% CI = 2.44-54.78, P = 0.0200, respectively. 262 
Furthermore, HIV patients was carried out in 14 patients in SJS/TEN case and 61 patients in 263 
tolerant group. The HLA-B*15:02 and HLA-B*38:02 showed significant difference with CTX-264 
induced SJS/TEN (OR = 5.09, 95% CI = 1.28-20.25, P = 0.0208, OR = 8.40, 95% CI = 2.07-265 
34.03, P = 0.0029, respectively). Additionally, the association between HLA-C*07:27 and HLA-266 
C*08:01 and CTX-induced SJS/TEN was also observed with OR of 24.60 (95% CI = 1.11-267 
544.28, P = 0.0427 and OR of 10.74 (95% CI = 2.18-52.90, P = 0.0035, respectively. Whilst, 268 
there was no association between HLA-A, B and C alleles and CTX-induced SCARs in HIV-269 
negative patients. 270 
Pooled-data analysis 271 
The allele frequencies of HLA-A*11:02, HLA-B*15:02 and C*08:01 in CTX-induced 272 
SJS/TEN and tolerant controls are shown in Table 7 after pooling our results with those obtained 273 
by Kongpan et al. The frequency of  HLA-B*15:02 and HLA-C*08:01 in CTX-SJS/TEN were 274 
significantly higher than the frequency found in tolerant controls (OR = 4.25, 95% CI = 1.83-275 
9.88, P = 0.0008 and OR = 4.12, 95% CI = 1.72-9.90, P = 0.0015, respectively). Nevertheless, 276 
no significant difference was observed when the frequency of HLA-A*11:02 was compared 277 
between CTX-SJS/TEN cases and tolerant controls (OR = 1.64, 95% CI = 0.86-3.16, P = 278 
0.1361). 279 
In subgroup analysis of HIV-positive patients, two HLA alleles, HLA-B*15:02 and 280 
C*08:01 were significantly associated with CTX-SJS/TEN with OR of 5.77 (95%CI = 2.04-281 
16.30, P = 0.0009) and 11.05 (95%CI = 2.97-41.07, P = 0.0003), respectively. Whilst, there was 282 
no association between HLA-A*11:01, HLA-B*15:02 and HLA-C*08:01 and CTX- induced 283 
SCARs in HIV-negative patients (data not shown).  284 
Discussion 285 
SJS, TEN, and DRESS are potentially fatal SCARs affecting multiple organs and 286 
systems, and CTX has been implicated as a trigger for these adverse drug reactions.23, 24 The 287 
hypersensitivity reaction should be occurred approximately 2 to 7 weeks after first exposure. The 288 
previous studies presented the range of drug exposure time of CTX patients was 1 to 74 days.
12   
289 
However, some of our patients appear to be outside of a recognized window of drug exposure. 290 
The latency was more than 7 weeks. Several studies have provided evidences of the genetic 291 
predisposition to SCARs in various populations.25 In this study, we examined HLA risk factors 292 
for CTX-induced SCARs among Thai patients. We identified that carriers of HLA-B*15:02 and 293 
HLA-C*08:01 alleles are significantly more likely to develop SJS/TEN, while the HLA-B*13:01 294 
allele was associated with an increased risk of developing DRESS in patients taking CTX. None 295 
of the HLA-A alleles showed a significant association with CTX-induced SCARs. The haplotype 296 
analysis revealed a significant increase in the frequency of HLA-A*11:01-B*15:02 and HLA-297 
B*13:01-C*03:04 haplotypes in the CTX-induced SJS/TEN and DRESS cases, respectively. 298 
However, the haplotype data was imputed by statistical program.  299 
The association between the HLA class I and HLA-DRB1 polymorphisms and CTX-300 
induced SJS/TEN was first reported in a Thai population by Kongpan et al. 12 in which they 301 
demonstrated an increased frequency of HLA-B*15:02, HLA-C*06:02, and HLA-C*08:01 in 302 
CTX-induced SJS/TEN patients with risk being about 4-fold higher among patients with the 303 
HLA-B*15:02 or HLA-C*08:01 alleles and 12 folds higher among patients with HLA-C* 06:02.12 304 
In the present study, we replicated the association with HLA-B*15:02 and HLA-C*08:01 but not 305 
with HLA-C*06:02. The HLA-A*02:07 and HLA-A*33:03 alleles were more common in the 306 
controls than in cases suggesting that they may protect against the development of CTX-induced 307 
SJS/TEN in Thai patients. However, these alleles did not reach statistical significance after 308 
Bonferroni correction (P > 0.0025).  309 
HLA-B*15:02 is primarily associated with carbamazepine-induced SJS/TEN in patients of 310 
certain Asian ethnicities.26 Interestingly, our study provides evidence that  same HLA allele may 311 
predispose to SJS/TEN caused by either carbamazepine or CTX. It should be noted that HLA-312 
C*08:01 was the only allele significantly associated with SJS/TEN after Bonferroni’s correction 313 
for multiple comparisons in the previous study by Kongpan et al.12 In our present study, HLA-314 
C*08:01 allele showed a significant association with SJS/TEN, suggesting that this allele may 315 
also have a role in SJS/TEN induced by CTX. Whether HLA-C*08:01 is a clinically relevant 316 
marker for CTX-induced SJS/TEN need to be investigated in other populations. 317 
The carrier frequency of the HLA-B*13:01 allele in CTX-induced SCAR cases did not 318 
differ significantly from the tolerant controls after corrections for multiple testing (P >0.0025). 319 
However, HLA-B*13:01 showed a significant association with CTX-induced DRESS (P 320 
<0.0025). This observation suggests that HLA-B*13:01 is a risk factor that is specific for CTX-321 
induced DRESS. It indicates that the individual phenotypes do not share the same risk locus in 322 
the HLA system. The frequency of HLA-C*03:04 allele was also significantly higher in CTX-323 
induced DRESS as compared to the healthy controls, and the haplotype analysis revealed a 324 
significant increase in the frequency of the HLA-B*13:01-C*03:04 haplotype in the DRESS 325 
group. These haplotype results are different from the previous report in Thai population.11 HLA-326 
B*13:01  has convincingly been shown to be a risk factor for dapsone hypersensitivity syndrome 327 
in Han Chinese and Thai populations.27, 28 HLA-B*13:01 has a well-defined sub-pocket within 328 
the antigen-binding site which fits the dapsone molecule and potentially alters self-peptides upon 329 
binding.29 Given the structural similarities between sulfamethoxazole and dapsone, and in their 330 
respective metabolic pathways, our finding of an association with HLA-B*13:01 is thus 331 
biologically plausible. 332 
Nonetheless, HLA-A alleles; HLA-A*11:01, HLA-A*11:02, HLA-A*31:01, HLA-A*33:03, 333 
HLA-A*68:01 and HLA-A*74:01 have shared peptide binding specificities
30
 and 26 of 30 of the 334 
cases carry one or more of these alleles. It is notable that immune response of drug interact to 335 
HLA binding groove can be shared across HLA molecules with similar peptide binding 336 
specificity
31
. In present study, seven patients (100%) who are reported HIV-negative carried 337 
HLA-A*11:01. Two of four HIV-negative patients with SJS/TEN have HLA-B*15:02 and HLA-338 
C*08:01, whereas three of three HLA-negative patients with DRESS patients also carried HLA-339 
B*13:01. Interestingly, the association between HLA alleles and CTX-induced SCARs was 340 
found in HIV infected patients but not HIV-negative patients. It is possibly that HIV itself could 341 
be related to this association due to systemic reduction of glutathione in HIV-infected patients
32
.  342 
Pharmacological interaction of drugs with immune receptors, the so-called p-i concept 343 
has been proposed to explain how T cells can be stimulated by the interaction of 344 
sulfamethoxazole with T cell receptors (TCR), and resulting in clinical symptoms of drug 345 
hypersensitivity.
10,11
 However, whether a specific T-cell function leads to a specific clinical 346 
phenotypes is unclear, and so further research is needed and should be based on well-347 
characterized phenotypes and drug causality, considering the heterogeneity of T-cell function.
33
 348 
There is a theoretical possibility of cross-reactivity between sulfonamide antibiotics and non-349 
antibiotic sulfonamides,
34





Some of the limitations of our study should be considered before interpreting the results. 351 
First, this research only studied the role of class I HLA alleles and CYP2C9, but not other HLA 352 
and drug metabolism enzyme genes and host factors. Apart from CYP2C9 enzyme, N-353 
acetyltransferases and glutathione-S-transferases play important roles in sulfamethoxazole 354 
metabolism to reactive metabolites and toxicity detoxification, respectively
36,37
. Chang et al. 355 
reported that high daily doses of CTX were an independent risk factor for cutaneous and other 356 
ADRs.38 We did not measure the serum concentrations of CTX, so it is possible that plasma and 357 
tissue concentrations of CTX might have influenced the adverse outcomes in our study. 358 
However, a previous case-control study by Pirmohamed et al. failed to demonstrate an 359 
association between genetic polymorphisms in drug metabolizing enzymes with CTX 360 
hypersensitivity in HIV patients
39
. Nonetheless, the in vitro study on sulfamethoxazole 361 
hypersensitive patients demonstrated HLA-DQ plays a critical role in the activation of drug 362 
metabolite (SMX-NO)-specific CD4+ T cells. Further validation of other HLA and genetic 363 
polymorphisms in drug metabolism enzyme genes and host factors, or even in vitro study on 364 
drug specific T cells should be conducted. Second, there were few cases of CTX-induced 365 
SJS/TEN and DRESS. Nevertheless, despite limited power, we have identified phenotype-366 
specific HLA associations, and present patient-level data for the SJS/TEN and DRESS cases in 367 
our study to allow for further replication. Third, there was evidence that a strong association 368 
between SJS/TEN and trimethoprim alone was found
14
. However, no in vitro or in vivo patch test 369 
was not performed to validate the culprit drug as sulfamethoxazole or trimethoprim in this study. 370 
The number needed to test to prevent one case of co-trimoxazole induced SCARs have been 371 
done in the study. The estimated number needed to test of HLA-B*13:01-induced CTX-DRESS 372 
and HLA-B*15:02-induced CTX-SJS/TEN was 23 and 31, respectively.  373 
In conclusion, this study has highlighted the importance of HLA class I alleles or 374 
haplotypes in predisposing to evaluating their influence on the susceptibility to CTX-induced 375 
SCAR in Thai patients. Most importantly, our data indicates that the association with HLA class 376 
I alleles may be phenotype-specific.  Of course, our data need further replication in larger 377 
numbers of patients and in different ethnic groups.  Given the public health drive to prevent 378 
SCAR caused by drugs in Thailand through the use of genotyping, we need to consider whether 379 
the alleles identified in this study should be utilized in the future to prevent SCAR from CTX. 380 
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Study Highlights 384 
1. What is the current knowledge on the topic? 385 
 Until now, only one study reported the association of HLA alleles and CTX-386 
induced SJS/TEN in Thai population.  387 
 The relationship between HLA alleles and CTX-induced SCARs remains unclear. 388 
 There is no published data on the genetic association with other SCAR 389 
phenotypes such as DRESS in Thai population.  390 
2. What questions did this study address? 391 
 Which HLA genes are associate with CTX-induced SJS/TEN and DRESS? 392 
 Do they have different biomarkers in different CTX-induced manifestation? 393 
3. What does this study add to our knowledge? 394 
 HLA-B*15:02 and HLA-C*08:01 alleles were significantly associated with CTX-395 
induced SJS/TEN 396 
 The HLA-B*13:01 allele was significantly associated with CTX-induced DRESS.  397 
 In addition, a significant higher frequency of HLA-A*11:01-B*15:02 and HLA-398 
B*13:01-C*03:04 haplotypes were detected in the group of CTX-induced 399 
SJS/TEN and DRESS cases, respectively  400 
4. How might this change clinical pharmacology or translational science? 401 
 Genetic association of co-trimoxazole-induced severe cutaneous adverse reactions 402 
is phenotype-specific.  403 
 Screening of the risk alleles is recommended for Thai patients before initiating 404 
CTX therapy. 405 
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1. Table S1 518 
2. Table S2 519 
Table 1. Study population’s demographics 
 Co-trimoxazole hypersensitive 
patients (n=30) 
Co-trimoxazole tolerant patients 
(n=91) 
Type of SCARs n (%)   
SJS 13 (43.33) 0 
TEN 4 (13.33) 0 
SJS/TEN overlap 1 (3.33) 0 
DRESS 12 (40.00) 0 
Gender n (%)   
Male 18 (60.00) 54 (59.34) 
Female 12 (40) 37 (40.66) 
Age   
Mean±SD 40.90±13.94 45.31±12.28 
Median (range) 41 (19-69) 45 (13-74) 
Indication of drug administration n (%)   
HIV 23 (76.67) 61 (67.03) 
Other diseases 7 (23.33) 30 (32.97) 
Onset of reaction   
Mean±SD 23.88±15.82 0 
Median (range) 17 (3-65) 0 
Co-morbidity n (%)   
HIV 23 (76.67) 61 (67.03) 
TB 3 (10.00) 2 (2.20) 
Other diseases 4 (13.33) 19 (20.88) 
No co-morbidity 3 (10.00) 17 (18.68) 
SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; DRESS, drug 
reaction with eosinophilia and systemic symptoms; HIV, Human Immunodeficiency Virus; TB, tuberculosis. 




Indication for                       
co-trimoxazole 
HLA class I genotyping 
CYP2C9 
HLA-A HLA-B HLA-C 
1 M/57 DRESS HIV 02:07/11:01 13:01/46:01 01:02/03:04 *1/*1 
2 F/21 DRESS HIV 24:02/24:02 13:01/40:01 03:04/07:27 *1/*1 
3 M/21 SJS HIV 11:01/24:07 15:02/38:02 07:27/08:01 *1/*1 
4 M/29 SJS HIV 11:01/32:01 15:02/44:02 05:01/08:01 *1/*1 
5 M/39 SJS HIV 02:03/74:01 13:01/51:01 04:06/14:02 *1/*1 
6 M/63 DRESS HIV 11:01/11:01 07:05/38:02 07:02/07:02 *1/*1 
7 F/19 DRESS N/A 11:01/33:03 13:01/58:01 03:02/03:04 *1/*1 
8 F/30 SJS HIV, Disseminated TB 11:01/33:01 44:03/58:01 03:02/07:01 *1/*1 
9 M/52 SJS HIV, HCV infection 11:01/31:01 35:03/38:02 04:01/18:01 *1/*1 
10 M/33 SJS HIV, pulmonary TB 02:02/24:02 46:01/48:01 01:02/08:03 *1/*1 
11 M/48 TEN HIV 02:01/02:03 13:01/38:02 03:04/07:27 *1/*1 
12 F/32 DRESS HIV 11:01/24:02 15:01/40:01 04:01/04:03 *1/*1 
13 F/23 SJS HIV, pulmonary TB 11:01/11:01 15:25/38:02 04:03/07:02 *1/*1 
14 M/20 DRESS HIV 11:01/24:10 13:01/18:02 03:04/07:04 *1/*1 
15 M/36 SJS HIV 11:01/11:01 07:05/15:02 07:02/08:01 *1/*1 
16 F/69 DRESS HIV 02:07/11:02 13:01/46:01 01:02/03:04 *1/*1 
17 F/31 DRESS PCP in HIV 11:01/24:02 13:01/15:02 03:04/08:01 *1/*1 
18 M/47 SJS PCP in HIV 02:03/33:03 18:01/44:03 07:01/07:04 *1/*1 
19 M/48 DRESS PCP in HIV 11:01/11:01 13:01/46:01 01:02/04:03 *1/*1 
20 F/59 DRESS Melioidosis 11:01/68:01 08:01/13:01 04:03/07:02 *1/*1 
21 M/46 DRESS Melioidosis 02:07/11:01 13:01/46:01 01:02/03:04 *1/*1 
22 M/57 DRESS PCP in HIV 11:01/24:07 07:05/15:02 07:27/08:01 *1/*1 




Indication for                       
co-trimoxazole 
HLA class I genotyping 
CYP2C9 




N/A 02:03/11:01 15:02/18:01 07:04/08:01 *1/*1 
25 F/46 TEN Melioidosis 11:01/26:01 08:01/51:01 07:02/14:02 *1/*1 
26 M/50 SJS PCP in HIV 24:02/74:01 07:05/38:02 07:02/07:02 *1/*1 
27 M/33 SJS PCP in HIV 24:02/29:01 07:05/15:02 08:01/15:05 *1/*1 
28 F/57 TEN Melioidosis 11:01/11:01 13:01/40:02 04:06/15:02 *1/*1 
29 M/37 TEN PCP in HIV 02:03/31:01 13:01/38:02 04:06/07:02 *1/*1 
30 M/43 SJS PCP in HIV 11:01/26:01 15:02/27:07 08:01/15:02 *1/*1 
* Age at the development of co-trimoxazole-induced SCARs; CYP2C9, cytochrome P450 2C9; DRESS, drug reaction with eosinophilia and systemic symptoms; F, Female; HCV, 
hepatitis C virus; HIV, Human Immunodeficiency Virus; HLA-A, human leucocyte antigen-A; HLA-B, human leucocyte antigen-B; HLA-C, human leucocyte antigen-C; M, Male; 
N/A, not available; PCP, Pneumocystis carinii pneumonia; SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TB, tuberculosis; TEN, toxic epidermal 
necrolysis.    
 
    
 
Table 3. The association of HLA class I alleles with co-trimoxazole-induced SCARs (n = 30) 
HLA class I alleles 
co-trimoxazole-
induced SCARs                        




Thai population       
(n = 150) 
co-trimoxazole-induced SCARs cases 
versus Tolerant controls 
co-trimoxazole-induced SCARs cases 
versus Thai population 
Odd ratio (95% CI) p-value < 0.05 Odd ratio (95% CI) p-value < 0.05 
HLA-A               
02:03 5 (16.67%) 19 (20.88%) 32 (21.33%) 0.76 (0.26 - 2.24) 0.6158 0.74 (0.26 - 2.08) 0.5637 
02:07 3 (10.00%) 28 (30.77%) 26 (17.33%) 0.25 (0.07 - 0.89) 0.0238 0.53 (0.15 - 1.88) 0.4209 
11:01 21 (70.00%) 38 (41.76%) 68 (45.33%) 3.25 (1.34 - 7.89) 0.0073 2.81 (1.21 - 6.55) 0.0136 
24:02 6 (20.00%) 17 (18.68%) 32 (21.33%) 1.09 (0.39 - 3.07) 0.8732 0.92 (0.35 - 2.45) 0.8702 
24:07 2 (6.67%) 5 (5.49%) 14 (9.33%) 1.23 (0.23 - 6.69) 1.0000 0.69 (0.15 - 3.23) 1.0000 
33:03 2 (6.67%) 18 (19.78%) 32 (21.33%) 0.29 (0.06 - 1.33) 0.1539 0.26 (0.06 - 1.17) 0.0609 
HLA-B 
       
07:05 5 (16.67%) 6 (6.59%) 8 (5.33%) 2.83 (0.79 - 10.07) 0.1379 3.55 (1.07 - 11.73) 0.0446 
13:01 13 (43.33%) 15 (16.48%) 23 (15.33%) 3.88 (1.56 - 9.63) 0.0025 4.22 (1.81 - 9.86) 4.7x10
-4
* 
15:02 9 (30.00%) 10 (10.99%) 27 (18.00%) 3.47 (1.25 - 9.63) 0.0201 1.95 (0.81 - 4.73) 0.1336 
38:02 7 (23.33%) 10 (10.99%) 12 (8.00%) 2.47 (0.85 - 7.19) 0.1273 3.50 (1.25 - 9.82) 0.0210 
40:01 2 (6.67%) 13 (14.29%) 18 (12.00%) 0.43 (0.09 - 2.02) 0.3529 0.52 (0.12 - 2.39) 0.5352 
46:01 5 (16.67%) 23 (25.27%) 40 (26.67%) 0.59 (0.20 - 1.72) 0.3323 0.55 (0.19 - 1.54) 0.2482 
58:01 2 (6.67%) 11 (12.09%) 12 (8.00%) 0.52 (0.11 - 2.49) 0.5152 0.82 (0.17 - 3.87) 1.0000 
HLA-C 
       
01:02 5 (16.67%) 23 (25.27%) 48 (32.00%) 0.59 (0.20 - 1.72) 0.3323 0.43 (0.15 - 1.18) 0.0926 
03:02 2 (6.67%) 13 (14.29%) 23 (15.33%) 0.43 (0.09 - 2.02) 0.3529 0.39 (0.09 - 1.77) 0.2612 
03:04 8 (26.67%) 21 (23.08%) 21 (14.00%) 1.21 (0.47 - 3.12) 0.6896 2.23 (0.88 - 5.67) 0.1027 
04:01 2 (6.67%) 5 (5.49%) 20 (13.33%) 1.23 (0.23 - 6.69) 1.0000 0.46 (0.10 - 2.10) 0.5398 
04:03 4 (13.33%) 13 (14.29%) 11 (7.33%) 0.92 (0.28 - 3.08) 1.0000 1.94 (0.58 - 6.58) 0.2821 
07:02 7 (23.33%) 26 (28.57%) 26 (17.33%) 0.76 (0.29 - 1.99) 0.5764 1.45 (0.56 - 3.74) 0.4382 
07:27 4 (13.33%) 0 (0%) 2 (1.33%) 31.08 (1.62 - 595.88) 0.0032 11.39 (1.98 - 65.37) 0.0076 
08:01 9 (30.00%) 9 (9.89%) 33 (22.00%) 3.91 (1.38 - 11.06) 0.0149 1.52 (0.64 - 3.63) 0.3443 
Haplotype        
HLA-A*11:01/-
B*15:02 
8 (26.67%) 7 (7.69%) 16 (10.67%) 4.36 (1.43 - 13.34) 0.0108 3.05 (1.17 - 7.96) 0.0343 
HLA-B*13:01/-
C*03:04 
8 (26.67%) 8 (8.79%) 10 (6.67%) 3.77 (1.27 - 11.19) 0.0251 5.09 (1.81 - 14.29) 0.0032 
HLA-A, human leucocyte antigen-A; HLA-B, human leucocyte antigen-B; HLA-C, human leucocyte antigen-C; SCARs, severe cutaneous adverse reactions; Significant different p-value < 0.05. 
P-values were calculated by Fisher’s exact test. Statistically significant values are highlighted in bold.  
*Corrected P- value was obtained after Bonferroni correction (Pc < 0.0025). 
 
Table 4. The association of HLA class I alleles with co-trimoxazole-induced DRESS (n = 12) 
HLA class I alleles 
co-trimoxazole-
induced DRESS  




Thai population       
(n = 150) 
co-trimoxazole-induced DRESS cases 
versus Tolerant controls 
co-trimoxazole-induced DRESS cases 
versus Thai population 
Odd ratio (95% CI) p-value < 0.05 Odd ratio (95% CI) p-value < 0.05 
HLA-A 
       
02:03 0  19 (20.88%) 32 (21.33%) 0.15 (0.01 - 2.62) 0.1167 0.15 (0.01 - 2.53) 0.1259 
02:07 3 (25.00%) 28 (30.77%) 26 (17.33%) 0.75 (0.19 - 2.98) 1.0000 1.59 (0.40 - 6.28) 0.4516 
11:01 10 (83.33%) 38 (41.76%) 68 (45.33%) 6.97 (1.45 - 33.67) 0.0067 6.03 (1.28 - 28.46) 0.0112 
24:02 3 (25.00%) 17 (18.68%) 32 (21.33%) 1.45 (0.36 - 5.94) 0.6978 1.23 (0.31 - 4.81) 0.7231 
24:07 1 (8.33%) 5 (5.49%) 14 (9.33%) 1.56 (0.17 - 14.64) 0.5338 0.88 (0.11 - 7.36) 1.0000 
33:03 1 (8.33%) 18 (19.78%) 32 (21.33%) 0.37 (0.05 - 3.04) 0.4579 0.34 (0.04 - 2.69) 0.4622 
HLA-B 
       
07:05 2 (16.67%) 6 (6.59%) 8 (5.33%) 2.83 (0.50 - 15.97) 0.2341 3.55 (0.66 - 18.99) 0.1622 
13:01 9 (75.00%) 15 (16.48%) 23 (15.33%) 15.20 (3.68 - 62.83) 7.2 x 10
-5
* 16.57 (4.17 - 65.85) 2.4 x 10
-5
* 
15:02 2 (16.67%) 10 (10.99%) 27 (18.00%) 1.62 (0.31 - 8.47) 0.6286 0.91 (0.19 - 4.39) 1.0000 
38:02 1 (8.33%) 10 (10.99%) 12 (8.00%) 0.74 (0.09 - 6.32) 1.0000 1.05 (0.12 - 8.80) 1.0000 
40:01 2 (16.67%) 13 (14.29%) 18 (12.00%) 1.20 (0.24 - 6.11) 0.6860 1.47 (0.29 - 7.24) 0.6452 
46:01 4 (33.33%) 23 (25.27%) 40 (26.67%) 1.48 (0.41 - 5.37) 0.5084 1.38 (0.39 - 4.82) 0.7365 
58:01 1 (8.33%) 11 (12.09%) 12 (8.00%) 0.66 (0.08 - 5.63) 1.0000 1.05 (0.12 - 8.80) 1.0000 
HLA-C 
       
01:02 4 (33.33%) 23 (25.27%) 48 (32.00%) 1.48 (0.41 - 5.37) 0.5084 1.06 (0.31 - 3.70) 1.0000 
03:02 1 (8.33%) 13 (14.29%) 23 (15.33%) 0.55 (0.07 - 4.59) 1.0000 0.50 (0.06 - 4.08) 1.0000 
03:04 7 (58.33%) 21 (23.08%) 21 (14.00%) 4.67 (1.34 - 16.24) 0.0162 8.60 (2.49 - 29.63) 9.7 x 10
-4
* 
04:01 1 (8.33%) 5 (5.49%) 20 (13.33%) 1.56 (0.17 - 14.64) 0.5338 0.59 (0.07 - 4.83) 1.0000 
04:03 3 (25.00%) 13 (14.29%) 11 (7.33%) 2.00 (0.48 - 8.38) 0.3930 4.21 (0.99 - 17.84) 0.0711 
07:02 2 (16.67%) 26 (28.57%) 26 (17.33%) 0.50 (0.10 - 2.44) 0.5050 0.95 (0.19 - 4.61) 1.0000 
07:27 2 (16.67%) 0 (0%) 2 (1.33%) 43.57 (1.96 - 969.96) 0.0126 14.80 (1.88 - 116.35) 0.0279 
08:01 2 (16.67%) 9 (9.89%) 33 (22.00%) 1.82 (0.34 - 9.65) 0.6133 0.71 (0.15 - 3.39) 1.0000 
Haplotype        
HLA-A*11:01/-
B*15:02 
2 (16.67%) 7 (7.69%) 16 (10.67%) 2.40 (0.44 - 13.17) 0.2813 1.68 (0.34 - 8.33) 0.6255 
HLA-B*13:01/-
C*03:04 
7 (58.33%) 8 (8.79%) 10 (6.67%) 14.53 (3.74 - 56.47) 1.8 x 10
-4
* 19.60 (5.26 - 72.99) 2.3 x 10
-5
* 
HLA-A, human leucocyte antigen-A; HLA-B, human leucocyte antigen-B; HLA-C, human leucocyte antigen-C; DRESS, drug reaction with eosinophilia and systemic symptoms; Significant different 
p-value < 0.05. P-values were calculated by Fisher’s exact test. Statistically significant values are highlighted in bold.  
*Corrected P- value was obtained after Bonferroni correction (Pc < 0.0025). 
 
Table 5. The association of HLA class I alleles with co-trimoxazole-induced SJS-TEN (n = 18) 
HLA class I alleles 
co-trimoxazole-
induced SJS-TEN  




Thai population       
(n = 150) 
co-trimoxazole-induced SJS-TEN cases 
versus Tolerant controls 
co-trimoxazole-induced SJS-TEN cases 
versus Thai population 
Odd ratio (95% CI) p-value < 0.05 Odd ratio (95% CI) p-value < 0.05 
HLA-A 
       
02:03 5 (27.78%) 19 (20.88%) 32 (21.33%) 1.46 (0.46 - 4.59) 0.5397 1.42 (0.47 - 4.27) 0.5511 
02:07 0  28 (30.77%) 26 (17.33%) 0.06 (0.01 - 1.03) 0.0058 0.13 (0.01 - 2.17) 0.0788 
11:01 11 (61.11%) 38 (41.76%) 68 (45.33%) 2.19 (0.78 - 6.17) 0.1315 1.89 (0.69 - 5.15) 0.2051 
24:02 3 (16.67%) 17 (18.68%) 32 (21.33%) 0.87 (0.23 - 3.35) 1.0000 0.74 (0.20 - 2.71) 0.7679 
24:07 1 (5.56%) 5 (5.49%) 14 (9.33%) 1.01 (0.11 - 9.22) 1.0000 0.57 (0.07 - 4.62) 1.0000 
33:03 1 (5.56%) 18 (19.78%) 32 (21.33%) 0.24 (0.03 - 1.91) 0.1893 0.22 (0.03 - 1.69) 0.2043 
HLA-B 
       
07:05 3 (16.67%) 6 (6.59%) 8 (5.33%) 2.83 (0.64 - 12.58) 0.1669 3.55 (0.85 - 14.83) 0.0987 
13:01 4 (22.22%) 15 (16.48%) 23 (15.33%) 1.45 (0.42 - 5.01) 0.5139 1.58 (0.48 - 5.22) 0.4959 
15:02 7 (38.89%) 10 (10.99%) 27 (18.00%) 5.16 (1.63 - 16.33) 0.0075 2.89 (1.03 - 8.16) 0.0576 
38:02 6 (33.33%) 10 (10.99%) 12 (8.00%) 4.05 (1.25 - 13.18) 0.0249 5.75 (1.83 - 18.05) 0.0054 
40:01 0 13 (14.29%) 18 (12.00%) 0.16 (0.01 - 2.77) 0.1206 0.19 (0.01 - 3.35) 0.2230 
46:01 1 (5.56%) 23 (25.27%) 40 (26.67%) 0.17 (0.02 - 1.38) 0.1151 0.16 (0.02 - 1.26) 0.0769 
58:01 1 (5.56%) 11 (12.09%) 12 (8.00%) 0.43 (0.05 - 3.54) 0.6862 0.68 (0.08 - 5.53) 1.0000 
HLA-C 
       
01:02 1 (5.56%) 23 (25.27%) 48 (32.00%) 0.17 (0.02 - 1.38) 0.1151 0.13 (0.02 - 0.97) 0.0197 
03:02 1 (5.56%) 13 (14.29%) 23 (15.33%) 0.35 (0.04 - 2.88) 0.4581 0.33 (0.04 - 2.56) 0.4749 
03:04 1 (5.56%) 21 (23.08%) 21 (14.00%) 0.19 (0.03 - 1.56) 0.1149 0.36 (0.05 - 2.86) 0.4729 
04:01 1 (5.56%) 5 (5.49%) 20 (13.33%) 1.01 (0.11 - 9.22) 1.0000 0.38 (0.05 - 3.03) 0.7037 
04:03 1 (5.56%) 13 (14.29%) 11 (7.33%) 0.35 (0.04 - 2.88) 0.4581 0.74 (0.09 - 6.12) 1.0000 
07:02 5 (27.78%) 26 (28.57%) 26 (17.33%) 0.96 (0.31 - 2.97) 0.9456 1.83 (0.60 - 5.59) 0.3323 
07:27 2 (11.11%) 0 (0%) 2 (1.33%) 27.73 (1.27 - 604.11) 0.0259 9.25 (1.22 - 70.19) 0.0573 
08:01 7 (38.89%) 9 (9.89%) 33 (22.00%) 5.79 (1.79 - 18.70) 0.0049 2.26 (0.81 - 6.28) 0.1417 
Haplotype        
HLA-A*11:01/-
B*15:02 
6 (33.33%) 7 (7.69%) 16 (10.67%) 6.00 (1.72 - 20.88) 0.0074 4.19 (1.38 - 12.69) 0.0165 
HLA-B*13:01/-
C*03:04 
1 (5.56%) 8 (8.79%) 10 (6.67%) 0.61 (0.07 - 5.20) 1.0000 0.82 (0.09 - 6.84) 1.0000 
HLA-A, human leucocyte antigen-A; HLA-B, human leucocyte antigen-B; HLA-C, human leucocyte antigen-C; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; Significant different 
p-value < 0.05. P-values were calculated by Fisher’s exact test. Statistically significant values are highlighted in bold.  
*Corrected P- value was obtained after Bonferroni correction (Pc < 0.0025). 
 
Table 6.  List of HLA alleles that showed a significant association with Co-trimoxazole-induced SCARs among the different subgroup. 
HLA class I alleles 
 HIV-positive patients HIV-negative patients 
co-trimoxazole-
induced SCARs  
+/Total                         
Tolerant controls 
+/Total                         
Odd ratio (95% CI) p-value 
co-trimoxazole-
induced SCARs  
+/Total                                                 
Tolerant controls 
+/Total                         




    
HLA-A*02:07 2/23 21/61 0.18 (0.04-0.85) 0.0302 1/7 7/30 0.54 (0.06-5.35) 0.6047 
HLA-A*11:01 14/23 23/61 2.57 (0.96-6.88) 0.0602 7/7 17/30 11.57 (0.61-220.97) 0.1037 
HLA-B*07:05 5/23 3/61 5.37 (1.17-24.70) 0.0308 0/7 3/30 0.52 (0.02-11.30) 0.6799 
HLA-B*13:01 9/23 9/61 3.71 (1.24-11.12) 0.019 4/7 6/30 5.33 (0.93-31.51) 0.0599 
HLA-B*15:02 7/23 6/61 4.01 (1.18-13.64) 0.0262 2/7 4/30 2.60 (0.37-18.25) 0.3365 
HLA-B*38:02 7/23 5/61 4.90 (1.37-17.54) 0.0146 0/7 5/30 0.31 (0.02-6.25) 0.4442 
HLA-C*07:27 4/23 0/61 28.38 (1.46-550.99) 0.0270 0/7 0/30 N/A N/A 
HLA-C*08:01 7/23 3/61 8.46 (1.96-36.47) 0.0042 2/7 6/30 1.60 (0.24-10.36) 0.6219 
DRESS         
HLA-A*11:01 7/9 23/61 5.78 (1.11-30.25) 0.0376 3/3 17/30 N/A N/A 
HLA-B*13:01 6/9 9/61 11.55 (2.44-54.78) 0.0021 3/3 6/30 N/A N/A 
HLA-C*07:27 2/9 0/61 41.00 (1.79-937.48) 0.0200 0/3 0/30 N/A N/A 
SJS/TEN         
HLA-A*11:01 7/14 23/61 1.65 (0.51-5.32) 0.3997 4/4 17/30 N/A N/A 
HLA-B*15:02 5/14 6/61 5.09 (1.28-20.25) 0.0208 2/4 4/30 N/A N/A 
HLA-B*38:02 6/14 5/61 8.40 (2.07-34.03) 0.0029 0/4 5/30 N/A N/A 
HLA-C*07:27 2/14 0/61 24.60 (1.11-544.28) 0.0427 0/4 0/30 N/A N/A 
HLA-C*08:01 5/14 3/61 10.74 (2.18-52.90) 0.0035 2/4 6/30 N/A N/A 
DRESS, drug reaction with eosinophilia and systemic symptoms; HLA-A, human leucocyte antigen-A; HLA-B, human leucocyte antigen-B; HLA-C, human leucocyte antigen-C; N/A, not available; 
SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; Significant different p-value < 0.05. 
P-values were calculated by Fisher’s exact test. Statistically significant values are highlighted in bold.  
 
Table 7. Pooled-data analysis comparing the frequencies of HLA-A*11:01, HLA-B*15:02 and C*08:01 in co-trimoxazole induced SJS/TEN and 
tolerant controls. Data were obtained from two studies with high-resolution HLA-B typing results.  

















Odds ratio  
(95% CI) 
P-value 
A*11:01 33 38 1.64 (0.86-3.16) 0.1361 23 22 1.94 (0.88-4.28) 0.0995 
Without A*11:01 28 53 21 39 
B*15:02 21 10 4.25 (1.83-9.88) 0.0008 17 6 5.77 (2.04-16.30) 0.0009 
Without B*15:02 40 81 27 55 
C*08:01 19 9 4.12 (1.72-9.90) 0.0015 16 3 11.05 (2.97-41.07) 0.0003 
Without C*08:01 42 82 28 58 
HLA-A, human leucocyte antigen-A; HLA-B, human leucocyte antigen-B; HLA-C, human leucocyte antigen-C; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; Significant 
different p-value < 0.05. P-values were calculated by Fisher’s exact test. Statistically significant values are highlighted in bold.  
 
